The mechanism by which the anti-PD1 treatment works is that PD1–PDL1 interactions inhibit T cell function [112], while CR is proposed to increase the levels of granzyme in CD8+ T cells responsible for tumor killing [102]. Here, PDCD1 is linked to neoplasm.